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Abstract
The research on the binding process of ligand to pyrazinamidase (PncA) is crucial for elucidating the inherent relationship
between resistance of Mycobacterium tuberculosis and PncA’s activity. In the present study, molecular dynamics (MD)
simulation methods were performed to investigate the unbinding process of nicotinamide (NAM) from two PncA enzymes,
which is the reverse of the corresponding binding process. The calculated potential of mean force (PMF) based on the
steered molecular dynamics (SMD) simulations sheds light on an optimal binding/unbinding pathway of the ligand. The
comparative analyses between two PncAs clearly exhibit the consistency of the binding/unbinding pathway in the two
enzymes, implying the universality of the pathway in all kinds of PncAs. Several important residues dominating the pathway
were also determined by the calculation of interaction energies. The structural change of the proteins induced by NAM’s
unbinding or binding shows the great extent interior motion in some homologous region adjacent to the active sites of the
two PncAs. The structure comparison substantiates that this region should be very important for the ligand’s binding in all
PncAs. Additionally, MD simulations also show that the coordination position of the ligand is displaced by one water
molecule in the unliganded enzymes. These results could provide the more penetrating understanding of drug resistance of
M. tuberculosis and be helpful for the development of new antituberculosis drugs.
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Introduction
Nicotinamidase is an important metabolic enzyme that can
hydrolyze nicotinamide (NAM) to nicotinic acid (NA) (Figure 1)
[1], always involved in the nicotinamide adenine dinucleotide
(NAD
+) salvage pathway of several pathogenic microorganisms
such as Borrelia burgdorferi [2], Brucella abortus [3], and Mycobacterium
tuberculosis [4]. Because of lacking a de novo NAD
+ biosynthetic
pathway like mammals [5,6], many pathogens have to rely on the
transformation from host’s NAM to their own NAD
+ by
nicotinamidase to keep the stabilization of NAD
+ concentrations
[2,7]. Consequently, the nicotinamidase activity is of particular
importance for the viability of these pathogens. Recently, targeting
NAD
+ biosynthesis as an antibiotic approach has been the intense
subject of scientific investigation [7,8]. Furthermore, the more
important reason why nicotinamidase has attracted widespread
attention is that the Mycobacterium tuberculosis nicotinamidase
(MtPncA) can convert the NAM analogue prodrug pyrazinamide
(PZA) into the bacteriostatic compound pyrazinoic acid (POA)
(Figure 1), hence the alternative name, pyrazinamidase (PncA) [9–
12]. PZA, in combination with rifampicin and isoniazid, is the
first-line drug recommended by the World Health Organization
for the treatment of tuberculosis [10,11,13,14]. The addition of
PZA to this regimen leads to a significant reduction in the length of
chemotherapy, allowing the conventional 9-month tuberculosis
treatment to be shortened to 6 months [15]. The latest research
has proved that the active form of PZA, POA, targets the
ribosomal proteins S1 (RpsA) of M. tuberculosis, a vital protein in
protein translation and the ribosome-sparing process of trans-
translation, hence a subsequent inhibition of trans-translation and
the shortened duration of tuberculosis chemotherapy [16]. But the
binding of PZA to MtPncA and activation by the enzyme are the
essential prerequisites before functioning as the effective antitu-
berculosis drug.
Despite the significance of PncA in the NAD
+ salvage pathway
and the PZA activation, its mechanism of action has not yet been
fully understood. Since mutations in pncA gene were found by
Scorpio and Zhang [17], a lot of researches have identified various
mutations in pncA gene that can lead to the loss of PncA activity,
which are thought to be highly correlated with the PZA resistance
in M. tuberculosis [18–23]. One of the most striking features of these
mutations is their diversity, with hundreds of mutations scattered
throughout the pncA gene, not only in the active site. In order to
interpret how the mutations result in the PZA resistance, the
structure/function relationships of PncA need to be deeply
comprehended. In 2001, Du and colleagues [24] established the
unliganded crystal structure of PncA from Pyrococcus horikoshii
(PhPncA), which shows that PhPncA has a Zn
2+ ion coordinated by
Asp52, His54 and His71, as well as a catalytic triad consist of
Asp10, Lys94 and Cys133. Recently, the crystal structures of the
Acinetobacter baumanii PncA (AbPncA) with NA and POA bound at
the active site were obtained in which the pyridine nitrogen of NA
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cation (assumed to be Zn
2+) [25]. In a more recent publication,
French et al. [26] reported several high-resolution crystal
structures of the nicotinamidase from Streptococcus pneumoniae
(SpNic) in unliganded and ligand-bound forms, even with a
trapped nicotinoyl thioester intermediates. These crystallography
data have provided structural evidence of several proposed
reaction intermediates and allowed for a more complete under-
standing of the reaction mechanism of PncA. Apart from the
above-mentioned researches, which mainly focus on the catalytic
mechanism and the active site residues, the latest crystallographic
experiment has highlighted the underestimated importance of
protein folding and thermal stability in the MtPncA activity [27].
Indeed, the active-site residues of PncA play a key role in
enzymatic catalysis and function, and should be responsible for the
activity loss of numerous mutations. But not all the mutations
inducing the activity loss occur in the active site [17–22], indicative
of the significance of the non-active-site residues in PncA function.
Among the residues, those in the binding pathway of ligand must
be quite crucial for prompting the entrance of ligand to active site
and proper orientation. However, a great number of the present
researches on PncA pay less attention to the detailed binding
process of ligand to PncA, which affirmably hinders the adequate
understanding of PncA’s function. The further work of ligand’s
binding or unbinding would be necessary for an in-depth
illustration of the importance of those non-active-site residues. In
this paper, the molecular dynamics (MD) simulation methods,
which have been successfully applied to many similar researches
[28–30], were used to explore the binding pathway of NAM to two
PncA enzymes from two different bacteria (AbPncA and SpNic).
Based on the steered molecular dynamics (SMD) simulations, the
potential of mean force (PMF) for three different pulling directions
was constructed to determine the most possible binding or
unbinding pathway. And then the role of some important residues
in the pathway was proposed by calculation and analysis of the
interaction energies between the ligand and two enzymes. Some
shared structural characteristics of PncA family were presented by
the superimposition and comparative analysis among several PncA
proteins. Our present work would be helpful for the further
research on PncAs and the development of new antituberculosis
drugs.
Results and Discussion
Construction of Two Initial Models
Up to now, the crystal structure of NAM-bound AbPncA has not
been obtained in the experiment. But an analog of AbPncA
enzyme, SpNic, has been crystallized together with several
different ligands, which involve not only NA but also NAM
[26]. Superimposition and comparison of these SpNic-ligand
complex structures show that in spite of different substituent
groups, each ligand binds to the catalytic metal Zn
2+ by the
nitrogen atom of its respective pyridine ring. In addition, the
proposed reaction mechanism of nicotinamidase also suggests that
the coordination bond of pyridine ring to Zn
2+ is always kept
during the whole catalytic process [25,26,31]. Consequently, it is
reasonable and reliable that NAM adopts the similar binding
mode to NA in AbPncA.
Two Systems’ Stability in Conventional Molecular
Dynamics Simulations
A total 13 nsfreeconventional MDsimulation, includinga 10 ns
simulation in the NPT ensemble, was performed for each enzyme-
ligandcomplexinordertorelaxthecollisionamongsomeatomsand
obtain a more stable conformation. The structural stability of two
enzymes was assessed by calculation of the root-mean-square-
Figure 1. Hydrolysis reaction of NAM and PZA catalyzed by PncA.
doi:10.1371/journal.pone.0039546.g001
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carbon atoms (Ca) of two enzymes were calculated by taking their
respective initial structures, i.e. crystal structures, as the reference
points. The rmsd values, as the function of simulation time,
demonstrate that the overall conformations of two proteins appear
to be equilibrated in a very short time at the beginning of the free
MD simulations (Figure S1 in the Supporting Information). The
rmsd values of all atoms and Ca atoms of AbPncA are generally
stabilized near 1.8 and 1.1 A ˚, respectively, and the corresponding
valuesofSpNicare1.7and0.9 A ˚;accordingly,itcanbeinferredthat
theoverallconformationsoftwoproteinshavebeenstable.Butsuch
the rmsd calculations have just estimated the global stability of the
conformationsandnotconsideredtheligandsandthelocalregionof
the proteins, especially the active site. In order to identify the local
stability of the active site, several physical parameters, including
some coordination bond lengths and dihedral angle values, were
monitoredwiththesimulationtimeattheNPTstages(FigureS2,S3,
S4).Theresultsindicatethatthebondlengthsofallthecoordination
bonds to the metal ion Zn
2+ keep stable in the simulations and their
average values, with the fluctuation of less than 10%, are very close
to thoseaverage values intheexperimental structures. Among these
coordination bonds, those of NAM to Zn
2+ in two proteins have the
nearly equal values to the crystal structures (Figure S2). The sulfur
atoms in the catalysis cysteine residues (Cys159 in AbPncA and
Cys136 in SpNic) have a bit longer distance to the carbonyl carbon
atomsofNAMthanthoseinthecrystalstructures(FigureS3),which
may be affected by the protonation of the sulfhydryl groups in the
cysteine residues. By the examination of the dihedral consisting of
the coordination oxygen atom of Asp, Zn
2+, the pyridine nitrogen
atomandthecarbonylcarbonatomofNAM,thepyridineringplane
of the ligand doesn’t display the rotation movement throughout the
whole simulation process, despite a difference of about 7u from the
experimental structures (Figure S4). All the checkon the interaction
details suggests that the active sites of two proteins are locally stable.
In general, the global and local conformations of the two complexes
both validate the stability at the free MD stages, which is really
necessary for the sequential SMD simulations.
Unbinding Pathway of Nicotinamide
The constant velocity SMD (cv-SMD) simulations were per-
formed to pull the ligand NAM along the predetermined different
directions. Through careful inspection of the NAM binding sites in
two enzymes, as well as comparative analysis of the NAM-PncA
interaction and the proposed catalytic mechanism [25,26], three
possible pathways were chosen to carry out the SMD simulations
(Figure 2). In AbPncA, three direction vectors are as follows: (1)
Direction 1 is determined by the vector from Phe21 HE1 to NAM
CE2 (the name in the force field); (2) Direction 2 is the vector from
Wat2142 OH2to NAM CE2;(3)Direction3 is fromAsp54 OD2 to
NAM CE2 (Figure 2(a)). And in SpNic (Figure 2(b)), three directions
are Direction 1 (the vector from Wat204 OH2 to NAM CE2),
Direction 2 (the vector from Asp53 OD1 to NAM CE1) and
Direction 3 (the vector from Asn72 OD1 to NAM NZ), in which
Direction 1 and 2 are quite similar to each other but different from
Direction 3 (Here, we chose two similar pathways in SpNic with the
aim of validating the rationality of methods and evaluating the
choice of pathways). The superimposition with the rmsd value of
2.3 A ˚ ofCaatomsbetweentwoproteinsindicatesthatDirection1in
AbPncAissimilartoDirection3inSpNic,andDirection2inAbPncA
is similar to Direction 1 and 2 in SpNic. For each direction in two
proteins, six SMD simulations were performed with the stiff spring
constant.Figure3hasjustdepictedthesixcurvesofthepullingforces
exerted on NAM along Direction 2 in AbPncA. All the other curves
alsoshowthesimilarchangingbehavior.Thelargefluctuationofthe
applied forces in the pulling process results from the stiff spring
constant, 10000 pN/A ˚. The large spring constant can ensure that
the reaction coordinate follows closely the point to which it is
constrained. It has been shown by the monitoring of the SMD
trajectories that the displacement of the mass center of NAM has a
simple linear relationship with the time axis.It can been found from
Figure 3 that during the dissociation process of NAM, the exerted
forces keep increasing in initial stage, and after reaching a
maximum, the values of the pulling forces begin to drop down,
implyingtheescapeoftheligandfromthebondageoftheresiduesin
the active site. However, some other residues in the pathway still
have effect on the unbinding of NAM, and they will be analyzed in
detail below.
The potential of mean force (PMF) was constructed from six
repeated cv-SMD simulations for each of the predefined
directions, in which the direction with the lowest energy barrier
can be regarded as the most possible unbinding or binding
pathway. The calculated PMF profiles were recorded in Figure 4.
It can be observed from Figure 4(a) that in the pathway along
Direction 2 there is the lowest free energy barrier, about 40 kcal/
mol, and the pathways along Direction 1 and 3 are both
energetically unfavorable for the ligand’s dissociation from
AbPncA. So the pathway along Direction 2 is the most possible
pathway for ligand’s unbinding, of course also for its binding. In
SpNic (Figure 4(b)), due to the similarity between Direction 1 and
2, two PMF curves coincide well with each other and their energy
barriers, around 27 kcal/mol along Direction 1, are lower than
that in the pathway along Direction 3. Thus the pathway along
Direction 1 or 2 are more favorable for NAM’s unbinding or
binding. As mentioned above, the superimposition of two proteins
proves that Direction 2 in AbPncA corresponds to Direction 1 and
2i nSpNic; on the other hand, for two proteins, their respective
lowest energy barriers exist in the pathways along these two similar
directions. Therefore, such the pathway could be their general
unbinding/binding pathway. Further, due to the structural
similarity of all kinds of nicotinamidases, it is speculated that the
above-mentioned pathway also applies to the other enzymes. In
spite of the lowest energy barriers in each protein, two minima (40
vs. 27 kcal/mol) have the difference of 13 kcal/mol, which is
ascribed to the different position of the active sites in two proteins.
In comparison, the active site in AbPncA is buried in the interior of
the protein while that in SpNic is close to the surface of the protein.
Therefore the ligand in SpNic is susceptible to the external
environment, such as solvent, and its combination with the protein
is weaker than that with AbPncA, which results in the lower free
energy barrier.
Important Residues Affecting Ligand’s Unbinding or
Binding
Based on the optimal pathways determined above, many
important residues affecting the binding/unbinding of NAM can
be explained by the calculations of interaction energies between
the ligand and the proteins. In the ligand’s dissociation process, the
analyses of the total interaction energy between NAM and two
proteins reveal that the van der Waals (Vdw) interaction is
dominant relative to the electrostatic interaction, which is in good
agreement with the observation that the unbinding pathways in
two proteins mainly consist of the hydrophobic residues. It also
suggests that the aromatic ring of the ligand dominates the
binding/unbinding process, so the improvement or design of drug
with more hydrophilic substitutional groups may decrease its
binding activity with the target proteins in spite of possible higher
affinity in the final complex states.
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unbinding pathways have different effects on the interaction of
NAM with two proteins. And the interaction energies between the
ligand and all the important residues have been calculated and
presented in Figure 5, in which the electrostatic interaction
energies are marked as the black curves, the Vdw interaction
energies are the green curves, and the total interaction energies are
the red ones. The total interaction energies between these residues
and NAM all possess the minimum lower than 23 kcal/mol, and
display better consistency among six SMD trajectories. Notice that
the main interaction of NAM with most residues is the Vdw
interaction, which keeps consistent with the above results. In
AbPncA, a special residue is Ile154. The interaction energy
between the residue and NAM gradually decreases with the
displacement of NAM. Besides, the residue mainly interacts with
the ligand by the electrostatic force. By the inspection of the SMD
simulation trajectories, it is found that a hydrogen bond is formed
between the main-chain carbonyl group of the residue and the
amide group of NAM, and the side chain of the residue is
relatively far from NAM. The oxyanion hole, consisting of two
main-chain amides of cis-Ala155 and Cys159, also interacts with
NAM by the electrostatic force, whereas the interaction of NAM
with the two residues is not as strong as that with Ile154. In
Figure 5(a), the other residues, except Ile154, display the minima
during the unbinding process of the ligand, which play the
impeditive role in the dissociation of NAM. Among them, the
minimum for Phe21 appears at the beginning, and those for
Leu27, Phe73 and Ile184 emerge at the latter stage, which is
Figure 2. The pulling directions of NAM in two proteins: (a) AbPncA and (b) SpNic during the SMD simulations.
doi:10.1371/journal.pone.0039546.g002
Figure 3. Six profiles of the applied forces along Direction 2 in AbPncA.
doi:10.1371/journal.pone.0039546.g003
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interaction between Trp86 and NAM stabilizes near the lower
value in a longer time, which results from the relatively large side
chain size of Trp86. Some other residues, including Val29, Tyr123
and Phe158, have the modest effect on the dissociation of NAM,
with the total interaction energies more than 22.5 kcal/mol,
Figure 4. PMF profiles as a function of NAM’s displacement along the different directions in two proteins: (a) AbPncA and (b) SpNic.
doi:10.1371/journal.pone.0039546.g004
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binding.
The structural superimposition demonstrates that the residues
Phe14, Phe68, and Val131 in SpNic correspond to the residues
Phe21, Trp86, and Ile154 in AbPncA, respectively. The changing
trend of their interaction curves is also very similar. In comparison
with their counterpoint residues Ala155 and Phe158 of AbPncA,
the residues Leu132 and Ile135 of SpNic have the large interaction
energy with NAM, indicative of the stable Vdw interaction and
unstable electrostatic interaction. The catalysis residue Cys136 is
distinct from the corresponding residue Cys159 in AbPncA. In
SpNic, the stronger interaction comes up between Cys136 and
NAM, which is attributed to the double contribution of both the
electrostatic and Vdw interaction. The residue Leu21 displays
large fluctuation of interaction energies in different SMD
simulations. It may be caused by the exposure of the active site
in SpNic. Leu21 in SpNic apparently lacks the restraints from the
other residues, and features the larger degree of freedom. So the
residue has the great possibility of the side chain rotating during
the dissociation process of NAM.
Protein’s Changes after Ligand’s Dissociation
During the binding or unbinding process, the interaction
between NAM and the related residues of the proteins possibly
leads to some changes of the proteins’ structures. Herein we have
calculated the root-mean-square-fluctuation (rmsf) of the Ca
atoms of two proteins in the SMD simulations and illustrated
the relative motion in the interior of two proteins (Figure 6).
Figure 6(a) describes the conformation’s change of AbPncA in the
dissociation of the ligand. As seen in the figure, some parts of the
protein have produced the obvious changes as the ligand’s
unbinding, which mainly concentrate the region between b3 and
b4 sheets and a portion of a7 helix, surrounding the exit of the
unbinding pathway of NAM. Such the motion is also reflected in
the rmsf figure of the Ca atoms, in which the b3t ob4 parts of the
protein have the largest rmsf values, and secondly, the a7 helix
also possesses the considerable fluctuation. By careful investigation
on the SMD trajectories, the b3t ob4 portion of AbPncA is
observed to behave like a ‘‘gate’’, that is, when a ligand leaves from
the active site, the gate opens to the external environment, and in
contrast when a ligand is bound to the protein, the gate is closed to
lessen the exoteric effect on the ligand’s binding and protein’s
catalysis. However, in SpNic there is no similar portion to that
‘‘gate’’ in AbPncA. In SpNic, both the internal motion of protein
and the rmsf values of the Ca atoms show that the biggest
conformational change of the protein takes place in the region
between Glu56 and His62 and the whole a7 helix just has the
slight fluctuation (Figure 6(b)). Owing to the absence of the ‘‘gate’’
region, the active site in SpNic is exposed to the external
environment, so the ligand’s binding to the protein is liable to
be disrupted by the solvent. Hence such the binding is weaker than
that in AbPncA, and is easy to break, which is consistent with the
PMF results above-mentioned.
A recently obtained X-ray crystal structure of PncA from
Mycobacterium tuberculosis (MtPncA) provides us with a chance of
aligning the protein with the present-researched two proteins and
performing the comparative analysis [27]. Figure 7 shows the
structuralalignmentofthreeproteinsAbPncA(blue),SpNic(red)and
MtPncA (green) from Acinetobacter baumanii, Streptococcus pneumoniae
and Mycobacterium tuberculosis, respectively. Generally speaking, the
structure of AbPncA has the noticeable difference from that of the
other two proteins while SpNic and MtPncA have the quite similar
spatial structures. Just as mentioned above, there is a ‘‘gate’’ region
in Site 1 of AbPncA, while there is no such the region in the
correspondingsiteofSpNicthattheproteincan’tbinditssubstrateas
tightly as AbPncA. For MtPncA, its Site 1 region looks like neither
thatofAbPncAnorthatofSpNic.ThissiteinMtPncAiscomposedof
a loop region (Ile52-Trp68) with greater flexibility, which is just
located near the exit of ligand. Accordingly, this part of MtPncA is
thought to produce the bigger movement in the process of ligand’s
bindingorunbindingandthusdirectlyaffectthebindingactivityand
catalysisofsubstrate.Infact,aparticularmetal-coordinatedresidue,
His57, is just in the region. And the recent research [27] has also
highlightedtheimportanceofthisregion.Ontheotherhand,owing
to the absence of b-sheet like that in AbPncA, MtPncAmay not bind
substrateasstronglyasAbPncA.InSite2regionmarkedinFigure7,
it can be obviously seen that the conformation of AbPncA has some
significantdistinctionsfromthatoftheothertwoproteins.TheSite2
regionofAbPncAisfairlyclosetothebinding/unbindingpathwayof
ligand,whichisthereasonforitsfluctuating.Andthecorresponding
parts of MtPncA and SpNic are alike. According to the analysis of
SpNic, the region of MtPncA will also be stable. In spite of the
different spatial conformation of three proteins in Site 3 region as
described in Figure 7, on the basis of the investigation into the other
two proteins, it is speculated that the region of MtPncA would keep
the conformational stability during the binding/unbinding process
of ligand.
BecauseofthedirectcoordinationoftheligandNAMtothemetal
center,thegoingoftheligandfromtheactivesiteoftheproteinswill
induce the change of the metal ion coordination, in addition to the
transformation of the proteins’ conformation (Figure 8). The details
on the change process were found by the careful inspection of the
SMD trajectories. After the ligand departs from the metal ion Zn
2+
intheactivesiteofAbPncA,itscoordinationpositionempties,which
turns the metal ion into a penta-coordinated center. The case is
energeticallyunstable.Thenoneofthecoordinatedwatersmovesto
the coordination position of the ligand. Owing to the H-bond
interaction between the coordinated water molecules and Asp121,
the residue is pulled towards the metal ion by the locomotive water.
The result is that Asp121 replaces the shifted water to coordinate
with the metalion. The other coordination residues still stay intheir
original places. So Zn
2+ in the active site of AbPncA restores to the
hexa-coordinatedstructure(Figure8(a)).Thesamethinghappensto
SpNic. In the active site of SpNic, a residue Glu64, instead of the
coordinated water in AbPncA, directly coordinates to the metal ion.
After the ligand’s leaving, one water molecule from the external
solvent comes in and thus takes up the coordination position of
NAM. And the other coordination of Zn
2+ remains unchanged
(Figure 8(b)). By comparison, the active site configurations of two
proteins are very similar at the time of the absence of the ligand
(Figure8).Here,theresearchontheligand’sunbindingfromprotein
provides some clues about the binding of ligand to the proteins
because these two processes are quite the reverse.
Conclusions
In the present study, NAM, the analog of antituberculosis
prodrug PZA, were chosen as a probe to investigate the ligand’s
binding to the two PncA enzymes, AbPncA and SpNic. After the
Figure 5. Time dependence of all kinds of interaction energies between NAM and some related residues of two proteins: (a) AbPncA
and (b) SpNic during the SMD simulations. The Vdw interaction energies are colored in green, the electrostatic interaction energies in black and
the total interaction energies in red. The curves of the interaction energies represent the smoothed values from the FFT smoothing method of 50 ps.
doi:10.1371/journal.pone.0039546.g005
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unbinding directions were carried out on the basis of the SMD
simulations to determine the most possible binding pathway of the
substrate. The superimposition and comparison of the proteins
show that the determined binding pathways, with the lowest free
energy barriers, in two PncAs share much the same direction.
Further, owing to the structural similarity of all kinds of PncAs, it is
speculated that such the pathway should be the general binding or
unbinding pathway for all PncAs. After the ascertainment of the
most possible binding pathway, the calculations of interaction
energies shed light on some important residues affecting the
binding of ligand to PncA, which contain not only the active-site
residues but also the non-active-site ones. The unbinding or
binding of ligand also affects the structure of PncA. Two PncAs
chosen in our research both exhibit the greater extent relative
motion in the same region in the unbinding process of ligand. The
consistency of structural change in AbPncA and SpNic give us a
hint that the corresponding regions in the other PncAs will also
show the similar interior motion. The importance of the
determined regions for MtPncA has been highlighted by the
recent research [27]. Moreover, after the unbinding of ligand, the
active sites of two unliganded enzymes also display some similar
changes, namely, the coordination positions of NAM are taken up
by a water molecule. One special thing for AbPncA is that the
residue Asp121 near the active site coordinates with the metal ion
Zn
2+ after NAM departs. Our work could provide penetrated
insight into drug resistance of M. tuberculosis and would contribute
to the guideline for the new antituberculosis drug design.
Materials and Methods
Preparation of initial crystal structures were performed with the
Discovery Studio 2.5 software package [32] on a Dell Precision
WorkStation T5400. The conventional MD and SMD simulations
Figure 6. Conformational change of two proteins: (a) AbPncA and (b) SpNic together with the corresponding rmsf values of their Ca
atoms in the unbinding process of NAM.
doi:10.1371/journal.pone.0039546.g006
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program NAMD 2.6 [33]. Topology and force field parameters
were assigned from the CHARMM27 protein lipid parameter set
[34] for the proteins and from the CHARMM General Force
Field (CGenFF) parameter set [35] for the small molecule ligand
NAM.
Preparation of Initial Models
The initial models of MD simulations came from two X-ray
crystal structures: (i) NA-bound AbPncA (PDB ID: 2WT9) and (ii)
NAM-bound SpNic (PDB ID: 3O94) [25,26]. Both of the
structures contain more than one chain. In order to decrease the
system size, only chain A was retained to carry out the MD
calculations. The superimposition and comparison of several
structures from SpNic show that PncAs with NAM, NA and
nicotinoyl thioester are nearly same as each other in the active site
conformation. Based on the inspection, the NAM-bound AbPncA
may also be considered to be same as the NA-bound one. So the
NA ligand in 2WT9 was manually modified to be NAM by
Discovery Studio Visualizer [32]. Three glycerin molecules were
deleted in this pdb file. Besides, the C136S mutation in 3O94 was
also restored to the normal Cys residue. Except the modifications
above, no other change was introduced in order to as much as
possibly preserve the initial structure.
Conventional Molecular Dynamics
The above-prepared final structures were used to perform the
conventional MD simulations. The missing atoms were added by
means of the VMD program [36]. TIP3P water model [37], with a
cubic box extending up to 10 A ˚ from the solute in each direction,
was used to solvate the whole protein-ligand complex. According
to the physiological concentration, 154 mM, the corresponding
Na
+ and Cl
2 ions were added to ensure the overall neutrality of
the system.
Periodic boundary conditions were applied to the system to
obtain consistent behavior. The cutoff distance of electrostatic
interaction was set to 12 A ˚. And the electrostatic interaction
between 1–4 atoms is taken into account. Van der Waals
interactions were gradually turned off at a distance between 12
and 14 A ˚. The particle mesh Ewald (PME) method [38,39] was
employed every one step for the computation of long-range
electrostatic forces. The pair list distance was 15.5 A ˚. The non-
bonded pair list was updated every 20 steps. An integration time
step of 1 fs was assumed. The whole system was first energy
minimized with 10000 steps of conjugate gradients, by keeping the
coordinates of protein backbone atoms and ligands restrained with
a spring constant of 20 kcal mol
21 A ˚ 22. After minimization, at the
same restraint, the temperature of the system was gradually
increased with Langevin dynamics [40] from 100 to 300 K by
stepwise reassignment of velocities every 2 ps. Then another 1 ns
MD simulation was performed, in which the constraint was
gradually decreased to 0 with a step length of 4 kcal mol
21 A ˚ 22.
And then an additional 3 ns simulation was carried out without
any constraint in the NVT ensemble. Following that, the pressure
of the system was coupled to a reference pressure of 1 bar with a
modified Nose ´-Hoover Langevin piston method [41]. In the NPT
ensemble, a total 10 ns MD simulation was implemented on the
whole system to ensure the accomplishment of the equilibrium.
The final equilibrium state was used for a restart point for further
SMD.
Steered Molecular Dynamics Simulation
In the SMD simulations, mimicking the AFM experiment,
time-dependent external forces are applied to ligand to facilitate
its unbinding from receptor, which usually could not be achieved
by the conventional MD simulations. In the NAMD implement,
SMD may be carried out with either a constant force applied to
an atom (or set of atoms) or by attaching a harmonic (spring-like)
restraint to one or more atoms in the system and then varying
either the stiffness of the restraint or the position of the restraint
Figure 7. Superimposition and structural comparison of three proteins: AbPncA (blue), SpNic (red) and MtPncA (green).
doi:10.1371/journal.pone.0039546.g007
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(cf) SMD and constant velocity (cv) SMD, respectively. In the
present study, the cv-SMD was adopted to calculate a so-called
potential of mean force (PMF) using Jarzynski’s identity [42,43].
In the cv-SMD simulations, the pulling velocity was set to
0.01 A ˚/ps, which has been used for the construction of PMF
profiles [44]. A large spring constant k (k=10000 pN/A ˚) was
used to ensure that the pulled atoms follow the constraint closely,
a condition known as the stiff spring approximation and required
for an efficient application of Jarzynski’s identity [44,45]. When
performing the pulling simulations, the Zn
2+ ion, together with
the Ca atoms of its coordination residues, was kept to fix. An
external steering force was applied on the mass center of ligand
along the pre-defined directions (see Results and Discussion
section). The pulling force experienced by the reference point
was calculated by employing eq 1:
F(t)~k(vt{x) ð1Þ
where k is the force constant for pulling spring and x is the
displacement of reference point from its original position. During
the SMD simulations, the steering force was only applied along
the pulling direction. The ligand was free from constraint in the
plane perpendicular to pulling direction. The trajectories were
saved for every 0.1 ps, and steering forces were recorded for
every 20 fs. The SMD simulation for each pulling direction was
repeated for six times with the same starting structure and the
different random seeds.
PMF Calculation Based on Jarzynski’s Equality
The free energy change along a reaction coordinate, which is
termed the potential of mean force (PMF), was calculated by
Jarzynski’s Equality on the basis of the repeated SMD simulations.
Jarzynski’s Equality establishes a connection between equilibrium
free energies calculation and nonequilibrium work output, and
allows us to calculate PMF under nonequilibrium processes such
as SMD simulations [42,44–48]. The formula of Jarzynski’s
Equality is as follow:
e{bDF~Se{bW0?lT ð2Þ
where DF represents the free energy change between the initial
and final states, W0Rl is the work performed from state 0 to state l
in the SMD simulation, and b=(kBT)
21, where kB and T are the
Boltzmann constant and temperature, respectively. When the
pulling speed in a SMD simulation is low enough that the process
can be thought to be reversible, the work of the applied force is
equal to the free energy difference of the system between the initial
and final states. However, because of limited computing power,
such a process is often simulated at a speed several orders of
magnitude higher than the quasi-static speed, and besides
simulations can sample only a small number of trajectories. In
such a case, the exponential average term in broken brackets on
the right-hand side of formula (2) is difficult to estimate as a result
of large statistical errors caused by insufficient sample data. To
prevent this problem, some necessary approximation methods are
introduced, one of which is the expansion of Jarzynski’s Equality
by cumulant expansion as follows:
DF~SWT{
b
2
SW2T{SWT
2 
z    ð3Þ
If the distribution of work W shows Gaussian, the third- and
higher-order cumulants are identically zero and the second-order
cumulant expansion formula can be utilized to suppress statistical
error [44]. Therefore the present PMF calculations were carried
out by the second-order cumulant expansion formula. The
estimators based on Jarzynski’s equality were used for estimating
the convergence of the free energy [44].
Supporting Information
Figure S1 RMSD profiles for all atoms and Ca atoms of two
PncAs: (a) AbPncA and (b) SpNic with respect to their respective
reference structures (crystal structures) in the 13 ns free MD
simulations.
(TIF)
Figure S2 Time dependence of all the Zn-coordinated bond
lengths in the active sites of two PncAs: (a) AbPncA and (b) SpNic in
the 10 ns NPT MD simulations. The straight lines in the figure
represent the corresponding values of those bond lengths in the
experimental structures, i.e. the crystal structures.
(TIF)
Figure S3 Fluctuations of the distances between NAM carbonyl
C atoms and the catalytic cysteine S atoms (Cys159 in AbPncA and
Cys136 in SpNic) in two PncAs: (a) AbPncA and (b) SpNic during
the 10 ns NPT MD simulations.
(TIF)
Figure S4 Change plots of a related dihedral in the active sites of
two PncAs: (a) AbPncA and (b) SpNic during the 10 ns NPT MD
simulations. The dihedral consists of the following four atoms: the
coordination O atoms of Asp residue (Asp54 in AbPncA and Asp53
in SpNic), the metal Zn ion, the pyridine N atom of NAM, and the
carbonyl C atom of NAM.
(TIF)
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